Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 9.22M P/E - EPS this Y 53.50% Ern Qtrly Grth -
Income -7.29M Forward P/E -0.61 EPS next Y 31.20% 50D Avg Chg -7.00%
Sales 18.6k PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 38.70 EPS next 5Y - 52W High Chg -79.00%
Recommedations 2.00 Quick Ratio 3.21 Shares Outstanding 0.91M 52W Low Chg 25.00%
Insider Own 10.64% ROA -81.69% Shares Float 826.30K Beta 3.16
Inst Own 1.12% ROE -269.29% Shares Shorted/Prior 104.87K/44.99K Price 0.89
Gross Margin 67.31% Profit Margin - Avg. Volume 70,109 Target Price 13.50
Oper. Margin -37,907.43% Earnings Date - Volume 11,859 Change -2.05%
About Heart Test Laboratories, Inc.

Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company focuses on applying AI-based technology to an ECG to expand and improve an ECG's clinical utility. It is developing AI-ECG solutions, a proprietary algorithm designed to detect impaired cardiac relaxation, or cardiac dysfunction, caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG, a resting 12-lead ECG that will incorporate its AI-ECG algorithm that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company is doing business as HeartSciences. Heart Test Laboratories, Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Heart Test Laboratories, Inc. News
12/16/24 HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
11/13/24 HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
10/14/24 HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
09/12/24 HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
09/12/24 HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
07/29/24 HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
07/26/24 Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
07:30 AM HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
07/11/24 HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
06/04/24 HeartSciences Regains Compliance with Nasdaq Listing Requirements
05/20/24 HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
04/24/24 HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
04/02/24 HeartSciences to Present at the LD Micro Invitational XIV Conference
03/26/24 HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
03/16/24 Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)
03/14/24 HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
03/12/24 HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
03/06/24 HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
02/26/24 HeartSciences Adds Key Advisor to its Scientific Advisory Board
02/12/24 HeartSciences Expands its Scientific Advisory Board